Q2
GILD — Q2 2026 Financial Report Analysis
Gilead grew revenue 10% to $7.8 billion on 12% HIV growth and a scaling Yeztugo launch, but $11.2 billion of acquired-IPR&D charges and a $1.75 billion Trodelvy write-off produced a $10.5 billion net loss and drained cash from $10.6 billion to $3.2 billion.